Thermo Fisher Scientific continues to strategize towards expanding its reach in the biotech industry. The company is reportedly planning to sell parts of its diagnostics unit for an estimated $4 billion. The biotech research firm is also expanding its mRNA collaboration, signaling consistent focus on diversification. Thermo Fisher unveiled next-generation mass spectrometers at ASMS 2025 aimed at revolutionizing biopharma applications and omics research. In addition, the company launched a new spectral flow cytometer to offer increased speed, versatility, and reliability to laboratories. Another major milestone has been the inauguration of an Advanced Therapies Collaboration Center in Greater San Diego to accelerate cell therapy development. However, the company faced some setbacks due to macroeconomic woes and stringent competition, reducing its 2025 profit forecast due to tariff hit and funding cuts for research. Despite these challenges, it managed to beat Q1 2025 earnings expectations amid an 'uncertain macroeconomic environment'. It also secured an mRNA deal and acquisition targeted at future growth, launched a sustainable centrifuge line, and finalized a deal with Solventum's purification and filtration unit.
Thermo Fisher Scientific TMO News Analytics from Tue, 01 Oct 2024 07:00:00 GMT to Sat, 14 Jun 2025 13:13:58 GMT -
Rating 8
- Innovation 7
- Rumor 6
